Document Detail

Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries.
MedLine Citation:
PMID:  9468068     Owner:  NLM     Status:  MEDLINE    
The primary objective of this study was to characterize a large cohort of patients receiving thrombolytic therapy for acute myocardial infarction with respect to the group with a prior event. Patients were randomly assigned to 1 of 4 thrombolytic strategies. Baseline characteristics, 30-day outcomes, and 1-year mortality were compared between patients with (n = 6,704) and without (n = 34,143) prior myocardial infarction. Patients with prior myocardial infarction presented to the hospital earlier than those having their first event, but institution of thrombolytic therapy was delayed. Mortality at 30 days (11.7% vs 5.9%, p = 0.001) and 1 year (17.3% vs 8.2%, p < 0.001) was greater among patients with prior infarction, and independent of other demographic variables. Accelerated alteplase was more effective than streptokinase or combination therapy (30-day mortality 10.4% vs 12.2%, p = 0.012; 1-year mortality 15.9% vs 17.8%, p = 0.041). Infarct vessel patency did not differ between those with and without prior myocardial infarction (67.3% vs 67% at 90 minutes, p = 0.92); however, recurrent ischemia was more common in patients with prior myocardial infarction. Patients with healed myocardial infarction should be educated to ensure early hospital admission if they develop symptoms suggestive of acute infarction, and upon hospital arrival should be promptly triaged to receive reperfusion therapy with accelerated alteplase.
D B Brieger; K H Mak; H D White; N S Kleiman; D P Miller; A Vahanian; A M Ross; R M Califf; E J Topol
Related Documents :
8990408 - Prognostic markers in thrombolytic therapy: looking beyond mortality.
3605128 - Comparison of thrombolytic therapy for acute myocardial infarction in rural and urban s...
3934538 - Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young s...
18020578 - Recombinant plasminogen activators: a comparative review of the clinical pharmacology a...
1735988 - Applicability of noncardioplegic coronary bypass to high-risk patients. selection of pa...
937358 - Evaluation of left ventricular function in patients with sickle cell anemia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  81     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-02-26     Completed Date:  1998-02-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  282-7     Citation Subset:  AIM; IM    
Department of Cardiology and the Joseph J. Jacobs Center for Vascular Biology, The Cleveland Clinic Foundation, Ohio 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrinolytic Agents / therapeutic use
Middle Aged
Myocardial Infarction / drug therapy*,  mortality
Myocardial Reperfusion*
Randomized Controlled Trials as Topic
Streptokinase / therapeutic use
Survival Analysis
Thrombolytic Therapy*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Usefulness of pulmonary regurgitation Doppler tracings in predicting in-hospital and long-term outco...
Next Document:  Clinical correlates and prognostic significance of early negative exercise tolerance test in patient...